Lumos Pharma Stock Revenue
Lumos Pharma fundamentals help investors to digest information that contributes to Lumos Pharma's financial success or failures. It also enables traders to predict the movement of Lumos Stock. The fundamental analysis module provides a way to measure Lumos Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lumos Pharma stock.
Lumos |
Lumos Pharma Company Revenue Analysis
Lumos Pharma's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Lumos Pharma Revenue | 2.05 M |
Most of Lumos Pharma's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lumos Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Lumos Pharma reported 2.05 M of revenue. This is 99.97% lower than that of the Biotechnology sector and 99.72% lower than that of the Health Care industry. The revenue for all United States stocks is 99.98% higher than that of the company.
Lumos Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lumos Pharma's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lumos Pharma could also be used in its relative valuation, which is a method of valuing Lumos Pharma by comparing valuation metrics of similar companies.Lumos Pharma is currently under evaluation in revenue category among its peers.
Lumos Fundamentals
| Return On Equity | -1.73 | |||
| Return On Asset | -0.7 | |||
| Operating Margin | (10.52) % | |||
| Current Valuation | 24.19 M | |||
| Shares Outstanding | 8.65 M | |||
| Shares Owned By Insiders | 32.69 % | |||
| Shares Owned By Institutions | 24.27 % | |||
| Number Of Shares Shorted | 54.33 K | |||
| Price To Earning | (2.37) X | |||
| Price To Book | 7.64 X | |||
| Price To Sales | 17.02 X | |||
| Revenue | 2.05 M | |||
| Gross Profit | 1.52 M | |||
| EBITDA | (36.57 M) | |||
| Net Income | (34.03 M) | |||
| Cash And Equivalents | 79.51 M | |||
| Cash Per Share | 9.49 X | |||
| Total Debt | 585 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 17.59 X | |||
| Book Value Per Share | 0.57 X | |||
| Cash Flow From Operations | (31.09 M) | |||
| Short Ratio | 0.59 X | |||
| Earnings Per Share | (4.28) X | |||
| Price To Earnings To Growth | (0.15) X | |||
| Target Price | 4.25 | |||
| Number Of Employees | 30 | |||
| Beta | 0.33 | |||
| Market Capitalization | 37.54 M | |||
| Total Asset | 40.64 M | |||
| Retained Earnings | (161.52 M) | |||
| Working Capital | 33.01 M | |||
| Current Asset | 115.78 M | |||
| Current Liabilities | 14.4 M | |||
| Net Asset | 40.64 M |
Pair Trading with Lumos Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lumos Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lumos Pharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Lumos Stock
If you are still planning to invest in Lumos Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lumos Pharma's history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |